Status:

COMPLETED

Response to Acute Exercise in Eating Disorders

Lead Sponsor:

University of Wisconsin, Madison

Collaborating Sponsors:

National Institute of Mental Health (NIMH)

Conditions:

Eating Disorders

Eligibility:

FEMALE

16-25 years

Phase:

NA

Brief Summary

Individuals with eating disorders (ED) represent a high-priority clinical population, with among the highest mortality rates of any psychiatric disorder, and driven exercise (DEx) is a symptom evidenc...

Detailed Description

Eating disorders (EDs) are among the deadliest of all psychiatric disorders. However, first-line treatments for EDs are effective for only roughly 40% of adolescent patients. One barrier to treatment ...

Eligibility Criteria

Inclusion

  • Aged 16-25
  • ED participants must meet full criteria for DSM-5 restrictive-spectrum eating disorders characterized by weight and shape concern, I.e., anorexia nervosa (AN); mild, moderate, or in partial remission), atypical AN, and OSFED -AN type only)
  • ED participants must be medically stable, and suitable for outpatient treatment
  • Biological Females, Assigned Female at birth
  • English Speaking

Exclusion

  • Those with a medical condition that precludes exercise (e.g., severe asthma) will be excluded for any contraindications
  • Biological Males, Assigned Male at birth
  • BMI less than 16 (over 18 years) or less than 75% expected body weight (under 18 years)
  • Reported intake on Eating Disorder Examination \<1000kcal daily
  • Current purging \>1x per day
  • Current regular episodes of objective binge eating (\>1x/wk)
  • Current self-report of loss-of control eating per the Eating Disorders Examination Interview
  • ED related hospitalization, partial hospitalization, or residential treatment in the past month
  • Any endorsed medical concerns related to physical activity (as probed in the phone screening questions regarding cardiovascular, pulmonary, or metabolic disease).
  • Major medical disorders (e.g., cancer, AIDS)
  • Physical discomfort or difficulty with blood draws
  • Psychotic disorders
  • Intellectual disabilities
  • Developmental disorders
  • Active substance use disorder
  • Current suicidal risk per the Ask Suicide Screening Questionnaire
  • Pregnancy
  • Psychiatric medications that have not been stable for at least 4 weeks
  • Acute sedatives / pain killers (e.g., benzodiazepines, opioids) and prescription stimulants (e.g., methylphenidate, amphetamines) are not permitted for the full day prior to the laboratory session. The noted short-term medication holds only apply to subjects taking the noted medications in cases used to treat ADHD or other psychiatric conditions
  • Resting heart rate \<50 beats per minute (assessed at screening visit)
  • Low blood pressure (\<90/60), (assessed at screening visit)
  • Daily cannabis use
  • History of light headedness or fainting during blood draws or physical activity
  • History of chest pain during physical activity
  • Bone, joint, cardiac, pulmonary, metabolic, or other medical conditions that may be worsened by physical activity (e.g., COPD, diabetes, hypertension) that are not currently addressed via medication or lifestyle change.
  • Physical disabilities that prohibit task performance (such as blindness or deafness)
  • Any other condition that the investigator believes might put the participant at risk for negative outcomes
  • Individuals with a restrictive eating disorder presentation that does not include weight and shape concern (ARFID) or that has primary binge eating (bulimia nervosa)
  • Indication of health risk associated with exercise on the Physical Activity Readiness Questionnaire

Key Trial Info

Start Date :

November 2 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 31 2025

Estimated Enrollment :

74 Patients enrolled

Trial Details

Trial ID

NCT06213883

Start Date

November 2 2023

End Date

July 31 2025

Last Update

August 6 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

University of California San Francisco

San Francisco, California, United States, 94158

2

University of Wisconsin-Madison

Madison, Wisconsin, United States, 53719